Denmark's patient compensation system has paid 31 people a combined 15 million Danish kroner, about $2.2 million, after they developed a rare optic nerve condition following treatment with Novo Nordisk's Wegovy or Ozempic. The condition is non-arteritic anterior ischemic optic neuropathy, known as NAION. The payouts were reported on November 19.

The payments are a significant signal, and they are not proof of causation. Denmark's system is a no-fault arrangement: it compensates patients for injuries that are likely related to treatment without requiring them to prove that a company was negligent or that the drug caused the harm. That distinction is the key to reading the story.

What the compensation means

The Danish Patient Compensation handled 94 claims, according to the reporting. It awarded compensation in 31 cases, rejected 29, and has 34 still pending. The payments come from the Danish state, not from Novo Nordisk.

The earlier tranches tell a similar story. Four patients received about 800,000 kroner in November 2025, and 27 patients had received more than $1.5 million by September 2026. The November awards add to that total.

A no-fault award is a judgment that the injury is severe enough and the connection plausible enough to merit compensation. It is not a determination that the drug is unsafe for the population that uses it. It is not a finding that the drug is defective. Those findings come from regulators and courts, and they have their own standards.

How the Danish system works

Denmark's patient compensation system is a public, no-fault arrangement. A patient who believes a treatment caused an injury can apply, and the system reviews the medical records and the evidence. If the injury is severe and the connection to treatment is plausible, the patient can receive compensation without suing the manufacturer.

That design is meant to be faster and less adversarial than litigation. It also means the awards are not a finding of product defect. A compensation decision can rest on a probability that the treatment contributed, while a court case has to meet a higher standard.

The number of rejected claims is part of the story. Of the 94 claims, 29 were rejected. A rejection does not mean the patient was not injured; it means the review did not find enough support for compensation. The pending claims will add to the picture.

What the research shows

The evidence on GLP-1 drugs and NAION has been building for several years. Regulators have relied on pooled trial data, spontaneous reports, and observational studies. The FDA's review found a small increase in cases among patients on a GLP-1 for at least a year, and the European Medicines Agency classified the condition as a very rare side effect of semaglutide.

Observational studies are useful and limited. They can show an association, and they can adjust for some risk factors, but they cannot rule out every source of confounding. The patients who take GLP-1 drugs have high rates of diabetes, obesity, and cardiovascular disease, and those conditions are themselves associated with optic nerve problems.

The mechanism is also uncertain. One hypothesis involves rapid changes in blood sugar or blood pressure, which can affect blood flow to the optic nerve. Another involves the drug's effects on the vascular system. Neither has been proven, and the research is ongoing.

What NAION is

NAION is an ischemic injury to the optic nerve. It can cause sudden vision loss in one eye, and the loss is often irreversible. There is no established treatment that restores the vision.

The condition is rare, and it occurs in people who have never taken a GLP-1 drug. The baseline risk is higher in adults over 50 and in people with diabetes, high blood pressure, or sleep apnea, which are also conditions common among the patients who use these medicines.

The overlap matters for the causal question. A patient who develops NAION while taking a GLP-1 may have developed it because of the drug, because of an underlying condition, or because of chance. A compensation system can award without resolving that question. A court or a regulator has to answer it.

The FDA warning

In early November, the Food and Drug Administration required a NAION warning in the warnings and precautions section of the labeling for all GLP-1 drugs, including Novo's Ozempic, Wegovy, and Rybelsus and Eli Lilly's Mounjaro and Zepbound.

The agency's pooled review of more than 125 trials found about 6 cases per 100,000 patients treated with a GLP-1 for at least a year, compared with fewer than 4 per 100,000 in patients on placebo or other diabetes drugs. The agency did not establish causation, and it described the risk as small.

The labeling change is a middle ground. It tells prescribers and patients to watch for the condition without declaring that the drug causes it. That is a common regulatory response when the evidence suggests an association but does not prove a mechanism.

Novo's position

Novo Nordisk disputes that its drugs cause NAION. The company has said it remains confident in the benefit-risk profile of its GLP-1 medicines, and it has pointed to the rarity of the condition and the benefits of the drugs.

The European Medicines Agency's safety committee classified NAION as a very rare side effect of semaglutide in June 2025, with an estimated frequency of up to 1 in 10,000 users. That classification is a signal, not a finding of causation, and it is consistent with the FDA's decision to add a warning without restricting the drugs.

Novo Nordisk built its recent growth on semaglutide, and the drug is central to the company's revenue. A safety controversy that reduces prescriptions would matter to the company's financial results as well as to patients. That commercial stake does not make the company's scientific position wrong, and it does explain why the company is defending the drugs vigorously.

The benefits are real and substantial. GLP-1 drugs reduce weight and improve glycemic control, and they have been shown to reduce cardiovascular risk in some populations. A patient weighing the risk of a rare eye condition against those benefits is making a decision that depends on the individual's health and history.

The drug class

GLP-1 receptor agonists mimic a gut hormone that increases insulin secretion, slows stomach emptying, and reduces appetite. The class includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. The drugs have become among the most prescribed in the world.

The benefits are substantial. The drugs produce weight loss, improve blood sugar control, and reduce cardiovascular events in some populations. For a patient with obesity and diabetes, the benefits can be life-changing.

The risks are also real. Gastrointestinal side effects are common. Rare but serious risks include pancreatitis, gallbladder disease, and the eye condition at issue here. The label is the place where those risks are disclosed, and the FDA's decision to add the NAION warning reflects the agency's judgment that the risk is worth disclosing even without proof of causation.

The litigation

Novo and Eli Lilly face hundreds of lawsuits in the United States alleging that they failed to disclose the vision risk. Both companies are contesting the claims.

The litigation will turn on the same questions the regulators have been navigating: what the companies knew, when they knew it, and what they told patients and doctors. The Danish compensation decisions are not binding in U.S. courts, but they may be cited as evidence that the connection was plausible enough for a government system to pay.

The cases will take years. The discovery process will produce documents, the trials will produce testimony, and the outcomes will depend on the specific facts of each case. The Danish awards are one data point in a much larger record.

What the label says now

The FDA's labeling change puts NAION in the warnings and precautions section for all GLP-1 drugs. That section is where the agency places risks that prescribers need to know and discuss with patients.

The warning does not tell patients to stop the drug. It tells them to watch for symptoms and report them. The prescriber's role is to weigh the risk against the benefit for each patient, and to document the conversation.

The label is also a signal to the companies. A warning section creates a duty to inform, and the failure to do so can support a claim. The litigation will test whether the companies met that duty before the warning was added.

What patients should do

Patients taking a GLP-1 should not stop the medication on the basis of this report. Stopping abruptly can affect blood sugar control and weight, and the decision should be made with the prescriber.

Patients should report sudden vision changes, especially in one eye, to their care team promptly. The warning is meant to prompt an evaluation, not to create alarm. Most patients will never experience the condition.

Patients who are considering a GLP-1 should discuss the benefits and the rare risks with their clinician, including the eye warning and their own risk factors. The decision is individual, the evidence is evolving, and the conversation with a clinician is the right place to weigh both.

Compensation is not causation

The Danish payments are a reminder that drug safety is a spectrum. A rare side effect can be serious enough to compensate without being common enough to change a label, and a label change can be warranted without proof of causation.

The story is being watched by regulators, lawyers, and patients. It is also being watched by the millions of people who take these drugs and by the clinicians who prescribe them, for whom the practical question is not the legal standard but the individual risk. The next developments will come from the pending claims, the U.S. litigation, and the research that follows. For now, the safest reading is the one the regulators are using, and the rest of the story will be written by the research and the courts: a rare risk worth warning about, set against benefits that remain substantial for the patients who need the drugs.

Primary sources

  1. Bloomberg, for the Danish compensation figures, the claim counts, and Novo's response.
  2. Quartz, for the total payout and the dollar conversion.
  3. Medical Daily, for the FDA labeling change, the pooled review figures, and the EMA classification.